Expression of TEL-AML1 Fusion Transcripts and Response to Induction Therapy in Standard Risk Acute Lymphoblastic Leukemia

References

• Golub T. R., Barker G. F., Stegmaier K., Gilliland D. G. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Molecular Aspects of Myeloid Stem Cell Development. Curr Top Microbiol Immunol, L Wolff, AS Perkins, 1996; 211: 279–-289
   Google Scholar
• Golub T. R., Barker G. F., Bohlander S. K., Hiebert S. W., Ward D. C., Bray-Ward P., Morgan E., Raimondi S. C., Rowley J. D., Gilliland D. G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 1995; 92: 4917–-4921
   PubMed Web of Science ®Google Scholar
• Golub T. R., Barker G. F., Lovett M., Gilliland D. G. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–-316
   PubMed Web of Science ®Google Scholar
• Wlodarska I., Mecucci C., Marynen P., Guo C., Franckx D., La Starza R., Aventin A., Bosly A., Martelli M. F., Cassiman J. J., Van den Berghe H. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995; 85: 2848–-2852
   PubMed Web of Science ®Google Scholar
• Buijs A., Sherr S., Van Baal S., van Bezouw S., van der Plas D., van Kessel A. G., Riegman P., Lekanne Deprez R., Zwarthoff E., Hagemeijer A., Grosveld G. Translocation (12;22)(p13;q11) in myeloproliferative disorders results infusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 1995; 10: 1511–-1519
   PubMed Web of Science ®Google Scholar
• Raynaud S., Cavé H., Baens M., Bastard C., Cacheux V., Grosgeorge J., Guidal-Giroux C., Guo C., Vilmer E., Marynen P., Grandchamp B. The 12;21 tranlocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87(7)2891–-2899
   PubMed Web of Science ®Google Scholar
• Rubnitz J. E., Downing J. R., Pui C.-H., Shurtleff S. A., Raimondi S. C., Evans W. E., Head D. R., Crist W. M., Rivera G. K., Hancock M. L., Boyett J. M., Buijs A., Grosveld G., Behm F. G. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. Journal of Clinical Oncology 1997; 15(3)1150–-1157
   PubMed Web of Science ®Google Scholar
• Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans E, Morgan G, Lucas G S, Liu Y JA. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in remission and predict clinical relapse. Blood 2000; 95: 815–9
   PubMed Web of Science ®Google Scholar
• Rowley J D. The role of chromosome translocations in leukemogenesis. Semin Hematol. 1999; 36: 59–72
   PubMed Web of Science ®Google Scholar
• Harrison C J, Radford-Weiss I, Ross F, Rack K, le Guyader G, Macintyre E. Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. Cancer Genet Cytogenet 1999; 112: 15–20
   PubMed Web of Science ®Google Scholar
• Wang J, Wang M, Liu J M. Transformation properties of the ETO gene, fusion partners in t(8;21) leukemias. Cancer res. 1997; 57: 2951–5
   PubMed Web of Science ®Google Scholar
• Speck N A, Stacy T, Wang Q, North T, Gu T L, Miller J, Binder A, Marin-Padilla M. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res. 1999; 59: 1789–1793
   PubMed Web of Science ®Google Scholar
• Shurtleff S. A., Buijs A., Behm F. G., Rubnitz J. E., Raimondi S. C., Hancock M. L., Chan G. C.-E, Pui C.-H., Grosveld G., Downing J. R. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985–-1989
   PubMed Web of Science ®Google Scholar
• Romana S. P., Poirel H., Leconiat M., Flexor M.-A., Mauchaffé M., Jonveaux P., Macintyre E. A., Berger R., Bernard O. A. High frequency of t(12:21) in childhood B-lineageacute lymphoblastic leukemia. Blood 1995; 86(11)4263–-4269
   PubMed Web of Science ®Google Scholar
• McLean T. W., Ringold S., Neuberg D., Stegmaier K., Tantravahi R., Ritz J., Koeffler H. P., Takeuchi S., Janssen J. W.G., Seriu T., Bartram C. R., Sallan S. E., Gilliland D. G., Golub T. R. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88(11)4252–-4258
   PubMed Web of Science ®Google Scholar
• Zuna J., Hrusák O., Kalinová M., Muzíková K., Stary J., Trka J. Leukemia. TEL/AML1 positivity in childhood ALL: average or better prognosis? 1999; 13: 22–-24
   Google Scholar
• Rubnitz J. E., Shuster J. J., Land V. J., Link M. P., Pullen D. J., Camitta B. M., Pui C.-H., Downing J. R., Behm F. G. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89(4)1143–-1146
   PubMed Web of Science ®Google Scholar
• Rubnitz J. E., Behm F. G., Wichlan D., Ryan C., Sandlund J. T., Ribeiro R. C., Rivera G. K., Hancock M. L., Relling M. V., Evans W. E., Pui C.-H., Downing J. R. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999; 13: 19–-21
   PubMed Web of Science ®Google Scholar
• Ford A M, Bennett C A, Price C M, Bruin M CA, Van Wering E R, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. USA. 1998; 95: 4584–4588
   PubMed Web of Science ®Google Scholar
• Wiemels J L, Ford A M, Van Wering E R, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057–1062
   PubMed Web of Science ®Google Scholar
• Wiemels J L, Cazzaniga G, Daniotti M., et al. Prenatal origin of acute lymphoblastic leukemia in children. Lancet 1999; 354: 1499–1503
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, Carroll A J, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallon S E, Sather H, Shuster J, Simon R, Trigg M, Uckun F, Ungerleider R. A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 1996; 14(1)18–24
   PubMed Web of Science ®Google Scholar
• Uckun F M, Gaynon P, Sensel M, Nachman J, Trigg M, Steinherz P, Hutchinson R, Bostrom B, Lange B, Sather H, Reaman G. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group Study. J. Clin. Oncol. 1997; 15(6)2214–2221
   PubMed Web of Science ®Google Scholar
• Uckun F M, Nachman J B, Sather H N, Sensel M G, Theil K, Kraft P, Steinherz P G, Lange B, Hutchinson R, Reaman G H, Gaynon P S, Heerema N A. Clinical Significance of Philadelphia Chromosome-Positive Pediatric Acute Lymphoblastic Leukemia in the Context of Contemporary Intensive Therapies: A Report from the Children's Cancer Group. Cancer 1998; 83(9)2030–2039
   PubMed Web of Science ®Google Scholar
• Uckun F M, Sensel M G, Sather H N, Gaynon P S, Arthur D C, Lange B J, Steinherz P G, Kraft P, Hutchinson R, Nachman J B, Reaman G H, Heerema N A. Clinical Significance of Translocation t(1;19) in Childhood Acute Lymphoblastic Leukemia in the Context of Contemporary Therapies: A Report From The Children's Cancer Group. J. Clin. Oncol. 1998; 16(2)527–535
   PubMed Web of Science ®Google Scholar
• Reaman G H, Sposto R, Sensel M G, Lange B J, Feusner J, Heerema N A, Leonard M, Holmes E, Sather H N, Pender-Grass T, Johnstone H, O'Brien R, Steinherz P, Zeltzer P, Gaynon P, Trigg M, Uckun F M. Treatment Outcome and Prognostic Factors for Infants with Acute Lymphoblastic Leukemia Treated on Consecutive Trials of the Children's Cancer Group. Journal of Clinical Oncology 1999; 17(2)445–455
   PubMed Web of Science ®Google Scholar
• Heerema N. A., Sather H. N., Sensel M. G., Lee M. K., Hutchinson R., Nachman J. B., Lange B. J., Steinherz P. G., Bostrom B., Saynon P. S., Arthur D. C., Uckun F. Chromosome arm 12p abnormalities in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Cancer 2000; 88: 1945–1954
   PubMed Web of Science ®Google Scholar
• Heerema N. A., Sather H. N., Sensel M. G., Liu-Mares W., Lange B. J., Bostrom B., Nachman J. B., Steinherz P. G., Hutchinson R., Gaynon P. S., Arthur D. C., Uckun F. M. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1999; 94: 1537–1544
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kazimiera J., Gajl-Peczalska K. J., Provisor A. J., Heerema N. A. Lineage specificity of chromosomal abnormalities in immunologically classified newly diagnosed childhood acute lymphoblastic leukemia patients. Blood 1989; 73: 271–-280
   PubMed Web of Science ®Google Scholar
• Mitelman F.E. ISCN 1995: An International System for Human Cytogenetic Nomenclature (1995). S. Karger, Basel 1995
   Google Scholar
• Gaynon P, Crotty M L, Sather H, Bostrom B, Nachman J, Steinherz P, Heerema N, Sarquis M, Tuel-Ahlgren L, Uckun F M. Expression of BCR-ABL, E2A-PBX1 and MLL-AF4 Fusion Transcripts in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Initiative. Leukemia & Lymphoma 1997; 26: 57–65
   PubMed Web of Science ®Google Scholar
• Uckun F M, Herman-Hatten K, Crotty M L, Sensel M G, Sather H N, Tuel-Ahlgren L, Sarquis M B, Bostrom B, Nachman J B, Steinherz P G, Gaynon P S, Heerema N A. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998; 92: 810–821
   PubMed Web of Science ®Google Scholar
• Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes, Chromsomes, & Cancer 1999; 26: 355–365
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Desai A, Bostrom B C, Hutchinson R, Nachman J B, Reaman G H, Sather H N, Steinherz P G, Trigg M E, Tübergen DG, Uckun F M. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer 1997; 80: 1717–1726
   PubMed Web of Science ®Google Scholar
• Kim D.-H., Moldwin R. L., Vignon C., Bohlander S. K., Suto Y., Giordano L., Gupta R., Fears S., Nucifora G., Rowley J. D., Smith S. D. TEL-AML1 translocations, TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood 1996; 88: 785–-794
   PubMed Web of Science ®Google Scholar
• Cavé H., Cacheux V., Raynaud S., Brunie G., Bakkus M., Cochaux P., Preudhomme C., Laï J.L., Vilmer E., Grandchamp B. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459–-1464
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Miller C. W., Reiter A., Seriu T., Zimmermann M., Schrappe M., Mori N., Slater J., Miyoshi I., Koeffler H. P. Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1. Blood 1996; 87: 3368–-3374
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Seriu T., Bartram C. R., Goiub T. R., Reiter A., Miyoshi I., Gilliland D. G., Koeffler H. P. TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1997; 11: 1220–-1223
   PubMed Web of Science ®Google Scholar
• Golub T. R., Goga A., Barker G. F., Afar D. E.H., McLaughlin J., Bohlander S., Rowley J. D., Witte O. N., Gilliland D. G. Oligomerization of the ABL tyrosine kinase by the ets protein TEL in human leukemia. Mol Cell Biol 1996; 16: 4107–4116
   PubMed Web of Science ®Google Scholar
• Loncarevic I. F., Roitzheim B., Ritterbach J., Viehmann S., Borkhardt A., Lampert F., Harbott J. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes, Chromosomes and Cancer 1999; 24(3)272–-277
   PubMed Web of Science ®Google Scholar
• Third International Workshop on Chromosomes in Leukemia (1980): Chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics 1981; 4: 101–-111
   PubMed Web of Science ®Google Scholar
• Raimondi S. C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237–-2251
   PubMed Web of Science ®Google Scholar
• Heerema N, Sather H, Sensel M, Shang T, Hutchinson R, Nachman J, Lange B, Steinherz P, Bostrom B, Gaynon P, Uckun F M. Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 Among Children With Acute Lymphoblastic Leukemia and High Hyperdiploidy (>50 Chromosomes). Journal of Clinical Oncology 2000
   Web of Science ®Google Scholar
• Raimondi S. C., Shurtleff S. A., Downing J. R., Rubnitz J., Mathew S., Hancock M., Pui C.-H., Rivera G. K., Grosveld G. C., Behm F. G. 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia. Blood 1997; 90: 4559–-4566
   PubMed Web of Science ®Google Scholar
• Fears S., Vignon C., Bohlander S. K., Smith S., Rowley J. D., Nucifora G. Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 1996; 17: 127–-135
   PubMed Web of Science ®Google Scholar
• Stegmaier K., Pendse S., Barker G. F., Bray-Ward P., Ward D. C., Montgomery K. T., Krauter K. S., Reynolds C., Sklar J., Donnelly M., Bohlander S. K., Rowley J. D., Sallan S. E., Gilliland D. G., Golub T. R. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 1995; 86(1)38–-44
   PubMed Web of Science ®Google Scholar
• Cavé H., Gerard B., Martin E., Guidal C., Devaux I., Weissenbach J., Elion J., Vilmer E., Grandchamp B. Loss of heterozygosity in the chromosomal region 12p12–13is very common in childhood acute lymphoblastic leukemia and permits the precise localization of a tumor-supressor gene distinct from p7KIPI. Blood 1995; 86: 3869–-3875
   PubMed Web of Science ®Google Scholar
• Sato Y., Suto Y., Pientenpol J., Golub T. G., Gilliland D. G., Davis E. M., Le Beau M. M., Roberst J. M., Vogelstein B., Rowley J. D., Bohlander S. K. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 1995; 9: 1525–-1533
   Google Scholar
• Höglund M., Johansson B., Pedersen-Bjergaard J., Marynen P., Mitelman F. Molecular characterization of 12p abnormalities in hematologic malignancies: Deletion of KIP1, rearrangement of TEL, and amplification of CCND2. Blood 1996; 87: 324–-330
   PubMed Web of Science ®Google Scholar
• Lanza C., Volpe G., Basso G., Gottardi E., Perfetto F., Cilli V., Spinelli M., Ricotti E., Guerrasio A., Madon E., Saglio G. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome. Leukemia 1997; 11: 820–-821
   PubMed Web of Science ®Google Scholar